Teva will invest $7.5 million in Cocrystal in exchange for an option to license exclusive rights to an HCV polymerase inhibitor

Cocrystal Discovery Inc.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Teva Pharmaceutical Industries Ltd.

Israel / Mid-Cap Biopharma ($1-$50 billion)

$36,110.9m on 09/16/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced